CCL2 and COVID-19: As a result, a severe form of COVID-19 with the development of ARDS and an increased level of pro-inflammatory cytokines in plasma, such as IL-1β, IL-6, TNF-α, chemokines—CXCL10 (IP-10), CCL2 (MCP-1), and CCL3 (MIP-1α), is characterized by low IFN-I levels in the blood at an early stage and increased IFN-I levels at a late stage of COVID-19 [197].